Disease Information

General Information of the Disease (ID: DIS00325)

• Name: Psoriasis
• ICD: ICD-11: EA90

Type(s) of Resistant Mechanism of This Disease

  ADTT: Aberration of the Drug's Therapeutic Target

  IDUE: Irregularity in Drug Uptake and Drug Efflux

Drug Resistance Data Categorized by Drug

Approved Drug(s) 2 drug(s) in total

Methotrexate

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Irregularity in Drug Uptake and Drug Efflux (IDUE)

Key Molecule: Multidrug resistance protein 1 (ABCB1) [1]

• Resistant Disease: Psoriasis [ICD-11: EA90.0]
• Molecule Alteration: SNP; rs1045642 TT
• Resistant Drug: Methotrexate
• Experimental Note: Identified from the Human Clinical Data
• Mechanism Description: The SNP of ABCB1 led to methotrexate resistance in the resistance.

Tildrakizumab

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: Interleukin 23 receptor (IL23R) [2]

• Sensitive Disease: Nail psoriasis [ICD-11: EA90.50]
• Molecule Alteration: Function; Inhibition
• Sensitive Drug: Tildrakizumab
• Experimental Note: Discovered Using In-vivo Testing Model
• Mechanism Description: Tildrakizumab, an IL-23 inhibitor, has shown significant clinical improvement in the treatment of moderate-to-severe chronic plaque psoriasis. We report 2 cases of treatment resistant nail psoriasis which showed marked improvement with the use of off-label tildrakizumab.

References

• Ref 1: ABCB1 in dermatology: roles in skin diseases and their treatment .J Mol Med (Berl). 2021 Nov;99(11):1527-1538. doi: 10.1007/s00109-021-02105-y. Epub 2021 Aug 9. 10.1007/s00109-021-02105-y
• Ref 2: Successful management of treatment resistant nail psoriasis with tildrakizumab .Australas J Dermatol. 2021 Aug;62(3):390-393. doi: 10.1111/ajd.13642. Epub 2021 Jun 11. 10.1111/ajd.13642